Lonza will expand its drug development in Switzerland yet again with investments in three of its manufacturing sites, the company announced Wednesday, capping off a very busy year ...
Accelerated approval for Merck’s Keytruda in a common form of liver cancer looked tenuous after a confirmatory study whiffed on two survival measures. But after ODAC recommended to ...
Sanofi is throwing in the towel on mRNA-based Covid-19 vaccines.
Perhaps anticipating a walkover with an FDA approval in hand, Biogen has instead faced a wall of pushback over its controversial Alzheimer's med Aduhelm. With payers and clinics ...
If you're already an Endpoints subscriber, enter your email below for a
magic link that lets you log in quickly without using a password. Please note the magic link is
one-time use only and expires after 24 hours.
We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.
ENDPOINTS NEWSby John Carroll & team — all the news at 11:30am ET
EARLY EDITIONby Arsalan Arif — news and links at 7:15am ET
ENDPOINTS MANUFACTURINGWeekly biopharma manufacturing report, Thursdays at 2pm ET
ENDPOINTS WEEKLYRecaps the most important developments on Saturday 6am ET
ENDPOINTS FDA+Regulatory news and analysis for drug developers, Wednesday 2pm ET
ENDPOINTS MARKETING RXCovers advertising and the multibillion-dollar drug commercialization world, Tuesday 2pm ET